期刊
CANCER TREATMENT REVIEWS
卷 38, 期 4, 页码 311-317出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2011.10.007
关键词
Anti-EGFR; Bladder cancer; Emerging treatments; Eribulin; mTOR inhibition; Nab-paclitaxel; PARP; Sorafenib; Sunitinib; Volasertib
类别
Urothelial carcinoma is one of the leading causes of death in Europe and the United States. Despite its chemosensitivity, median overall survival for advanced disease is still nearly 1 year. Most second-line chemotherapeutic agents tested have been disappointing. Thus, new treatment strategies are clearly needed. This review focuses on emerging therapies in urothelial carcinoma. Results from recent clinical trials, investigating the activity of new generation cytostatic agents, as well as results from studies assessing the toxicity and efficacy of novel targeted therapies, are discussed. In this setting, anti-epidermal growth factor receptor, angiogenesis, and phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors account for the majority of phase I and II trials. (c) 2011 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据